Rescuing High Avidity T Cells for Prostate Cancer Immunotherapy
Abstract
This is the second annual report on the grant "Rescuing high avidity T cells for prostate cancer immunotherapy". The purpose of the grant proposal is to rescuing high avidity tumor-antigen specific T cells that can respond effectively to prostate cancer cells and delay the delay the development of prostate cancer in the TRAMP mouse model. The innovative idea is based on the hypothesis that blockade of the T cell costimulatory pathway in adults will inhibit the deletion of high avidity tumor antigen specific T cells. We have proposed three specific aims in the grant. (I). Identify the cells in thymus that express peripheral tumor antigen to induce clonal deletion of tumor antigen reactive T cells. (2). Examine whether anti-B7 antibody treatment in TRAMP mice can rescue the tumor-antigen specific T cells that are otherwise deleted. (3). Determine the thymic function in prostate cancer patients undergoing hormonal therapy. In the past funding period, we have published two papers that summarized our results from specific aim 1. We have extended our study on the role of costimulatory molecule B7 on T cell early development and on NKT cell development. We have generated preliminary data on the treatment with lymphotoxin b receptor fusion protein to rescue the high avidity tumor antigen specific T cells. We have shown that anti-B7 treatment changed the regulatory T cell numbers and increased the survival time of TRAMP mice.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 01, 2005
- Accession Number
- ADA438256
Entities
People
- Pan Zheng
Organizations
- Ohio State University